Show simple item record

dc.contributor.authorAndrade D.C.
dc.contributor.authorHaine L.
dc.contributor.authorToledo C.
dc.contributor.authorDiaz H.S.
dc.contributor.authorQuintanilla R.A.
dc.contributor.authorMarcus N.J.
dc.contributor.authorIturriaga R.
dc.contributor.authorRichalet J.-P.
dc.contributor.authorVoituron N.
dc.contributor.authorDel Rio R.
dc.date.accessioned2020-09-02T22:12:21Z
dc.date.available2020-09-02T22:12:21Z
dc.date.issued2018
dc.identifier10.3389/fphys.2018.01440
dc.identifier.citation9, OCT, -
dc.identifier.issn1664042X
dc.identifier.urihttps://hdl.handle.net/20.500.12728/3570
dc.descriptionObstructive sleep apnea (OSA) is the most common form of sleep disordered breathing and is associated with wide array of cardiovascular morbidities. It has been proposed that during OSA, the respiratory control center (RCC) is affected by exaggerated afferent signals coming from peripheral/central chemoreceptors which leads to ventilatory instability and may perpetuate apnea generation. Treatments focused on decreasing hyperactivity of peripheral/central chemoreceptors may be useful to improving ventilatory instability in OSA patients. Previous studies indicate that oxidative stress and inflammation are key players in the increased peripheral/central chemoreflex drive associated with OSA. Recent data suggest that erythropoietin (Epo) could also be involved in modulating chemoreflex activity as functional Epo receptors are constitutively expressed in peripheral and central chemoreceptors cells. Additionally, there is some evidence that Epo has anti-oxidant/anti-inflammatory effects. Accordingly, we propose that Epo treatment during OSA may reduce enhanced peripheral/central chemoreflex drive and normalize the activity of the RCC which in turn may help to abrogate ventilatory instability. In this perspective article we discuss the potential beneficial effects of Epo administration on ventilatory regulation in the setting of OSA. Copyright © 2018 Andrade, Haine, Toledo, Diaz, Quintanilla, Marcus, Iturriaga, Richalet, Voituron and Del Rio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.subjectCentral chemoreflex
dc.subjectChronic intermittent hypoxia
dc.subjectErythropoietin
dc.subjectPeripheral chemoreflex
dc.subjectSleep apnea
dc.subjecterythropoietin
dc.subjecterythropoietin receptor
dc.subjectibuprofen
dc.subjectrecombinant erythropoietin
dc.subjectantiinflammatory activity
dc.subjectantioxidant activity
dc.subjectautonomic nervous system function
dc.subjectcell protection
dc.subjectchemoreceptor
dc.subjectchemoreceptor reflex
dc.subjectchronic intermittent hypoxia
dc.subjectdrug selectivity
dc.subjecthormone receptor interaction
dc.subjecthuman
dc.subjectneuroprotection
dc.subjectnonhuman
dc.subjectpathophysiology
dc.subjectrespiration center
dc.subjectrespiration control
dc.subjectrespiratory function
dc.subjectReview
dc.subjectsleep disordered breathing
dc.titleVentilatory and autonomic regulation in sleep apnea syndrome: A potential protective role for erythropoietin?
dc.typeReview


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record